Defective MMR genes and a subsequent increasing tumor mutational burden (TMB) and MSI are associated with the response to newly developed immune checkpoint inhibitors18, 19; however, MSI is very rare in pancreatic cancer and occurs in approximately 0.8–2% of cases.13, 20, 21. This evidence concerns the gene MRC1 and familial pancreatic carcinoma.